{"id":"betmiga","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypokalemia"},{"rate":"5-10%","effect":"Hyperkalemia"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Betmiba increases the levels of magnesium in the urine by inhibiting the reabsorption of magnesium in the kidneys. This helps to prevent the formation of kidney stones by increasing the concentration of magnesium in the urine, which can help to dissolve and prevent the growth of stones.","oneSentence":"Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:08.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of kidney stones"}]},"trialDetails":[{"nctId":"NCT07016451","phase":"EARLY_PHASE1","title":"Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis","status":"ENROLLING_BY_INVITATION","sponsor":"Thanakrit Visuthikosol","startDate":"2024-04-02","conditions":"Radiation Cystitis","enrollment":40},{"nctId":"NCT05968885","phase":"PHASE4","title":"Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2021-10-01","conditions":"Urinary Bladder, Overactive, Urodynamics, Effect of Drug","enrollment":300},{"nctId":"NCT02320773","phase":"","title":"A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-25","conditions":"Urgency Incontinence, Urinary Bladder Overactive, Overactive Bladder","enrollment":863},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases","enrollment":1524},{"nctId":"NCT03612401","phase":"EARLY_PHASE1","title":"Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-12-05","conditions":"Spinal Cord Injuries, Neurogenic Bladder, Cognitive Change","enrollment":20},{"nctId":"NCT02138747","phase":"PHASE4","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-07-24","conditions":"Overactive Bladder (OAB)","enrollment":376},{"nctId":"NCT02311569","phase":"PHASE2","title":"Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2015-04","conditions":"Myeloproliferative Neoplasm, Primary Myelofibrosis, Essential Thrombocythemia","enrollment":39},{"nctId":"NCT01898624","phase":"","title":"Specified Drug Use-results Survey of Betanis Tablets","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-12-04","conditions":"Overactive Bladder","enrollment":300},{"nctId":"NCT01901120","phase":"","title":"Long-Term Specified Drug Use-results Survey of Betanis Tablets","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10","conditions":"Overactive Bladder","enrollment":1263},{"nctId":"NCT02010944","phase":"PHASE1","title":"A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-09","conditions":"Phase 1, Bioavailability, Healthy Subjects","enrollment":72},{"nctId":"NCT01964183","phase":"PHASE4","title":"Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-06","conditions":"Pharmacokinetics of Mirabegron and Tolterodine, Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["YM178","Mirabegron","Myrbetriq®","Betanis®"],"phase":"phase_2","status":"active","brandName":"Betmiga®","genericName":"Betmiga®","companyName":"Astellas Pharma Europe Ltd.","companyId":"astellas-pharma-europe-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones. Used for Prevention of kidney stones.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}